SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Craig Hallum

Craig Hallum initiated coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note published on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $11.00 price target on the stock.

Several other equities research analysts have also commented on SABS. HC Wainwright reiterated a buy rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Oppenheimer reaffirmed an outperform rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Finally, Chardan Capital reaffirmed a buy rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a report on Monday, September 9th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of Buy and a consensus target price of $12.40.

SAB Biotherapeutics Price Performance

Shares of SAB Biotherapeutics stock opened at $2.40 on Wednesday. SAB Biotherapeutics has a one year low of $2.16 and a one year high of $10.50. The business has a 50-day simple moving average of $2.69 and a 200 day simple moving average of $3.19. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.07.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.34. The company had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. As a group, analysts anticipate that SAB Biotherapeutics will post -3.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. BVF Inc. IL purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at $6,310,000. Commodore Capital LP bought a new position in SAB Biotherapeutics in the 4th quarter worth $1,259,000. Finally, First PREMIER Bank purchased a new stake in SAB Biotherapeutics in the second quarter worth about $60,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.